These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 26746091)

  • 21. A prospective feasibility study of sentinel node biopsy by modified Indigocarmine blue dye methods after neoadjuvant chemotherapy for breast cancer.
    Kida K; Ishikawa T; Yamada A; Shimizu D; Tanabe M; Sasaki T; Ichikawa Y; Endo I
    Eur J Surg Oncol; 2015 Apr; 41(4):566-70. PubMed ID: 25650249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.
    Kuehn T; Bauerfeind I; Fehm T; Fleige B; Hausschild M; Helms G; Lebeau A; Liedtke C; von Minckwitz G; Nekljudova V; Schmatloch S; Schrenk P; Staebler A; Untch M
    Lancet Oncol; 2013 Jun; 14(7):609-18. PubMed ID: 23683750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of sentinel lymph node biopsy by ultrasound-guided core needle biopsy for patients with suspicious node positive breast cancer.
    Nakamura R; Yamamoto N; Miyaki T; Itami M; Shina N; Ohtsuka M
    Breast Cancer; 2018 Jan; 25(1):86-93. PubMed ID: 28735457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival-a propensity score cohort study.
    Fernandez-Gonzalez S; Falo C; Pla MJ; Campos M; Ortega-Exposito C; Ortega R; Vicente M; Petit A; Bosch-Schips J; Bajen MT; Reyes G; Martínez E; González-Viguera J; Peñafiel J; Stradella A; Pernas S; Ponce J; Garcia-Tejedor A
    Breast Cancer Res Treat; 2024 Jul; 206(1):131-141. PubMed ID: 38635082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sentinel node mapping performed before preoperative chemotherapy may avoid axillary dissection in breast cancer patients with negative or micrometastatic sentinel nodes.
    Schrenk P; Tausch C; Wölfl S; Bogner S; Fridrik M; Wayand W
    Am J Surg; 2008 Aug; 196(2):176-83. PubMed ID: 18513692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection.
    Armer JM; Ballman KV; McCall L; Ostby PL; Zagar E; Kuerer HM; Hunt KK; Boughey JC
    JAMA Surg; 2019 Sep; 154(9):800-809. PubMed ID: 31314062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome following sentinel lymph node biopsy-guided decisions in breast cancer patients with conversion from positive to negative axillary lymph nodes after neoadjuvant chemotherapy.
    Kang YJ; Han W; Park S; You JY; Yi HW; Park S; Nam S; Kim JH; Yun KW; Kim HJ; Ahn SH; Park S; Lee JE; Lee ES; Noh DY; Lee JW
    Breast Cancer Res Treat; 2017 Nov; 166(2):473-480. PubMed ID: 28766131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Omission of axillary lymph node dissection for clinically node negative early-stage breast cancer patients.
    Kobayashi R; Shiraishi K; Iwase S; Ohtomo K; Nakagawa K
    Breast Cancer; 2015 Nov; 22(6):657-63. PubMed ID: 24756246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. "This house believes that: Sentinel node biopsy alone is better than TAD after NACT for cN+ patients".
    Galimberti V; Ribeiro Fontana SK; Vicini E; Morigi C; Sargenti M; Corso G; Magnoni F; Intra M; Veronesi P
    Breast; 2023 Feb; 67():21-25. PubMed ID: 36566690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Laws A; Hughes ME; Hu J; Barry WT; Dominici L; Nakhlis F; Barbie T; Duggan M; Weiss A; Rhei E; Carter K; Nimbkar S; Schnitt SJ; King TA
    Ann Surg Oncol; 2019 Nov; 26(12):3846-3855. PubMed ID: 31222687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer. Its relation with molecular subtypes].
    Ruano R; Ramos M; García-Talavera JR; Ramos T; Rosero AS; González-Orus JM; Sancho M
    Rev Esp Med Nucl Imagen Mol; 2014; 33(6):340-5. PubMed ID: 24856234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
    Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
    Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.
    Caudle AS; Yang WT; Krishnamurthy S; Mittendorf EA; Black DM; Gilcrease MZ; Bedrosian I; Hobbs BP; DeSnyder SM; Hwang RF; Adrada BE; Shaitelman SF; Chavez-MacGregor M; Smith BD; Candelaria RP; Babiera GV; Dogan BE; Santiago L; Hunt KK; Kuerer HM
    J Clin Oncol; 2016 Apr; 34(10):1072-8. PubMed ID: 26811528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
    Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
    J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is Axillary Lymph Node Dissection Necessary After a Positive Sentinel Lymph Node Biopsy?
    Ozcan LC; Giuliano AE
    Adv Surg; 2017 Sep; 51(1):165-178. PubMed ID: 28797338
    [No Abstract]   [Full Text] [Related]  

  • 36. Survival after negative sentinel lymph node biopsy in breast cancer at least equivalent to after negative extensive axillary dissection.
    Kuijt GP; van de Poll-Franse LV; Voogd AC; Nieuwenhuijzen GA; Roumen RM
    Eur J Surg Oncol; 2007 Sep; 33(7):832-7. PubMed ID: 17197151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rates of pathologic nodal disease among cN0 and cN1 patients undergoing routine axillary ultrasound and neoadjuvant chemotherapy.
    Weiss A; King C; Vincuilla J; Parker T; Portnow L; Nakhlis F; Dominici L; Mittendorf EA; King TA
    Breast Cancer Res Treat; 2022 Sep; 195(2):181-189. PubMed ID: 35900704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is regional nodes radiotherapy an alternative to surgery?
    Offersen BV; Nielsen HM; Overgaard M; Overgaard J
    Breast; 2013 Aug; 22 Suppl 2():S118-28. PubMed ID: 24074772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study.
    Veronesi U; Viale G; Paganelli G; Zurrida S; Luini A; Galimberti V; Veronesi P; Intra M; Maisonneuve P; Zucca F; Gatti G; Mazzarol G; De Cicco C; Vezzoli D
    Ann Surg; 2010 Apr; 251(4):595-600. PubMed ID: 20195151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns in the Use of Axillary Operations for Patients with Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A National Cancer Database (NCDB) Analysis.
    Srour MK; Tseng J; Luu M; Alban RF; Giuliano AE; Chung A
    Ann Surg Oncol; 2019 Oct; 26(10):3305-3311. PubMed ID: 31342364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.